Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:


Written in Published in Earliest date Latest date

Sorted by

Results per page:

You searched for id:"handle:2115/74978". One record found.

Search Limiters

Last 2 Years | English Only

No search limiters apply to these results.

▼ Search Limiters

1. 和田, 雅孝. CHP-MAGE-A4がんワクチン臨床試験患者における末梢血CD4+CD25+FOXP3+制御性T細胞比率の臨床的意義に関する研究.

Degree: 博士(医学), 医学, 2019, Hokkaido University

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

和田, . (2019). CHP-MAGE-A4がんワクチン臨床試験患者における末梢血CD4+CD25+FOXP3+制御性T細胞比率の臨床的意義に関する研究. (Doctoral Dissertation). Hokkaido University. Retrieved from

Chicago Manual of Style (16th Edition):

和田, 雅孝. “CHP-MAGE-A4がんワクチン臨床試験患者における末梢血CD4+CD25+FOXP3+制御性T細胞比率の臨床的意義に関する研究.” 2019. Doctoral Dissertation, Hokkaido University. Accessed August 24, 2019.

MLA Handbook (7th Edition):

和田, 雅孝. “CHP-MAGE-A4がんワクチン臨床試験患者における末梢血CD4+CD25+FOXP3+制御性T細胞比率の臨床的意義に関する研究.” 2019. Web. 24 Aug 2019.


和田 . CHP-MAGE-A4がんワクチン臨床試験患者における末梢血CD4+CD25+FOXP3+制御性T細胞比率の臨床的意義に関する研究. [Internet] [Doctoral dissertation]. Hokkaido University; 2019. [cited 2019 Aug 24]. Available from:

Council of Science Editors:

和田 . CHP-MAGE-A4がんワクチン臨床試験患者における末梢血CD4+CD25+FOXP3+制御性T細胞比率の臨床的意義に関する研究. [Doctoral Dissertation]. Hokkaido University; 2019. Available from: